Tenax Therapeutics, Inc. (TENX)

Price$10.73

Value ScoreF

Growth ScoreF

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)5.86%

Price vs S&P 500 (4W)-7.97%

VGM Score26.89

Market Capitalization$284.61M

All Metrics

Book Value / Share (Quarterly)$4.72

P/TBV (Annual)3.79x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.57

Price vs S&P 500 (YTD)-20.13%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-10115.82%

EPS (TTM)$-1.40

10-Day Avg Trading Volume0.67M

EPS Excl Extra (TTM)$-1.40

EPS (Annual)$-1.34

ROI (Annual)-54.19%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-12872.94%

Cash / Share (Quarterly)$4.89

ROA (Last FY)-50.47%

Revenue Growth TTM (YoY)-82.93%

EBITD / Share (TTM)$-1.49

ROE (5Y Avg)-337.11%

Operating Margin (TTM)-10390.47%

Cash Flow / Share (Annual)$-3.84

P/B Ratio2.48x

P/B Ratio (Quarterly)2.40x

Net Income / Employee (Annual)$-3,757,100

EV / Revenue (TTM)3364.30x

Net Interest Coverage (TTM)-320.28x

ROA (TTM)-53.12%

EPS Incl Extra (Annual)$-1.34

Current Ratio (Annual)14.56x

Quick Ratio (Quarterly)14.01x

3-Month Avg Trading Volume0.48M

52-Week Price Return82.48%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$10164.00

P/S Ratio (Annual)5773.12x

Asset Turnover (Annual)0.00x

52-Week High$18.38

Operating Margin (5Y Avg)-10572.22%

EPS Excl Extra (Annual)$-1.34

Tangible BV CAGR (5Y)47.56%

26-Week Price Return13.79%

Quick Ratio (Annual)13.78x

13-Week Price Return-9.38%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)14.52x

Enterprise Value$165.86M

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-55.21%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)0.00x

Pretax Margin (Annual)-28563.49%

Cash / Share (Annual)$10.47

3-Month Return Std Dev94.08%

Gross Margin (5Y Avg)57.92%

Net Income / Employee (TTM)$-4,136,200

ROE (Last FY)-54.19%

Net Interest Coverage (Annual)-17.63x

EPS Basic Excl Extra (Annual)$-1.34

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.40

Receivables Turnover (Annual)0.00x

ROI (TTM)-56.32%

P/S Ratio (TTM)5773.12x

Pretax Margin (5Y Avg)-12872.94%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$17141.00

Price vs S&P 500 (52W)58.12%

Year-to-Date Return-11.98%

5-Day Price Return-10.36%

EPS Normalized (Annual)$-1.34

ROA (5Y Avg)-201.92%

Net Profit Margin (Annual)-28563.49%

Month-to-Date Return-9.60%

Cash Flow / Share (TTM)$-0.49

EBITD / Share (Annual)$-1.44

Operating Margin (Annual)-30054.16%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-292.37%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.40

P/TBV (Quarterly)1.04x

P/B Ratio (Annual)0.78x

Inventory Turnover (TTM)0.00x

Pretax Margin (TTM)-10115.82%

Book Value / Share (Annual)$10.42

Price vs S&P 500 (13W)-17.63%

Beta1.01x

Revenue / Share (TTM)$0.00

ROE (TTM)-56.32%

52-Week Low$5.34

vGradeF

gGradeF

mGradeC

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.35est. -0.41

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.36

4.33

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
TENXTenax Therapeutics, Inc.	F	F	C	$10.73
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Tenax Therapeutics is a specialty pharmaceutical company focused on cardiovascular and pulmonary diseases with high unmet medical needs. The company's lead asset is levosimendan (North American rights), currently in Phase 2 development for pulmonary hypertension associated with heart failure with preserved ejection fraction.